about
Molecular and cell-based therapies for muscle degenerations: a road under constructionAntisense mediated splicing modulation for inherited metabolic diseases: challenges for deliveryNanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophyCurrent understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophySkeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical TrialsDystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel TherapiesGEMINs: potential therapeutic targets for spinal muscular atrophy?Antisense therapy in neurologySplice-correction strategies for treatment of X-linked agammaglobulinemia.Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy.Duchenne muscular dystrophy gene therapy in the canine model.New multiplex real-time PCR approach to detect gene mutations for spinal muscular atrophy.Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy.The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype.Current Translational Research and Murine Models For Duchenne Muscular Dystrophy.Eteplirsen in the treatment of Duchenne muscular dystrophyAlternatively spliced mu opioid receptor C termini impact the diverse actions of morphine.Agammaglobulinemia: causative mutations and their implications for novel therapies.Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.Splicing modulation therapy in the treatment of genetic diseases.Small-scale high-throughput sequencing-based identification of new therapeutic tools in cystic fibrosis.Therapeutic strategies for spinal muscular atrophy: SMN and beyond.Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease.Modulation of nuclear REST by alternative splicing: a potential therapeutic target for Huntington's disease.Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.Skipping Multiple Exons to Treat DMD-Promises and Challenges.Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis.Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers.Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine
P2860
Q24568176-6E884FDB-7905-41ED-BB26-690227F4B065Q26830637-A51E86B7-8318-42F4-B32D-9B6E9D8F5A05Q26992271-432ECA8A-C6D2-4FF4-A528-66743B69076DQ28082625-EED25562-548C-47B7-8133-BA11747080C2Q31142754-3795FC4F-0169-4D58-82EB-41D9E332627FQ33608478-1052C00A-DCAA-4DD9-A588-A87A74FFC6D9Q34342044-780A22AC-99AC-4A2B-AB04-1382B5CA9CB6Q34608717-F48A7DB8-C1AC-436D-951A-88AF7BFF8E8DQ35033817-FEA6BC5A-EA96-4B23-BB05-0DF0A44B17C9Q35439476-23AACF07-24CE-4F3D-8099-A647229A3BDAQ35641673-DF799BA5-0FAC-440C-993D-08AC8BAF5878Q36106201-A8D2EE7C-940C-4A07-AD54-F29A48E3B406Q36484406-C775FFA1-594A-4C27-8C89-444E9B04704CQ36529176-0CFEF3DE-A65E-4660-ABDF-DF4F935A063BQ37610505-228363E6-7500-4B62-828D-CA80C87A114CQ37682676-76C6D33D-C45B-4B5F-909A-D61D8BE874A3Q37730688-17E5DF70-FB36-4690-ADB9-555543E67C30Q38161559-E134304F-3012-4CC3-8AC7-9DCA16CC61D3Q38186137-4699AD0D-D800-4C48-B9A1-78BBC8FC4B52Q38210259-F8131AE5-A1FD-4767-B2AE-A308A5127B3DQ38288237-017D9696-4DD7-46B2-B3A4-E3FE308A665AQ38922232-272E60B8-B069-406B-A352-AD9CAC20B667Q41440571-6EDAC541-542A-4908-9360-331178679B42Q41462957-F5E29D85-C3BF-41AE-A625-6B3131989EAAQ44573861-09E050C2-C090-48E8-ADF1-08DD1936F2B7Q47700306-CBF42DAE-9AF4-423B-828F-166B0EB576EEQ52429827-D8D7A75B-ADF4-4B01-BED8-881DB2F2873DQ53273994-56B44AC6-F102-4DC0-BDAF-6164863F331BQ55496176-48839F98-A076-4B57-AA4A-2ACFA68B7896Q58716650-541EA8EE-77D5-45F1-9932-7ED0831724B3
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Splicing therapy for neuromuscular disease
@ast
Splicing therapy for neuromuscular disease
@en
Splicing therapy for neuromuscular disease
@nl
type
label
Splicing therapy for neuromuscular disease
@ast
Splicing therapy for neuromuscular disease
@en
Splicing therapy for neuromuscular disease
@nl
prefLabel
Splicing therapy for neuromuscular disease
@ast
Splicing therapy for neuromuscular disease
@en
Splicing therapy for neuromuscular disease
@nl
P2860
P921
P3181
P1476
Splicing therapy for neuromuscular disease
@en
P2093
Andrew G.L. Douglas
Matthew J.A. Wood
P2860
P304
P3181
P356
10.1016/J.MCN.2013.04.005
P407
P5008
P577
2013-09-01T00:00:00Z